仑伐替尼为基础治疗在经治转移性肾细胞癌患者中的活性:欧洲多中心研究(LENVA-LAT)
该多中心回顾性研究纳入2020至2024年间接受仑伐替尼为基础治疗作为一线以上治疗的133例转移性肾细胞癌患者,中位年龄61岁,透明细胞型占82.0%。客观缓解率为29.1%,疾病控制率为67.7%,中位随访13.5个月时中位至治疗失败时间和总生存期分别为6.2个月和9.6个月。作者结论认为仑伐替尼为基础方案对重度经治患者有效且安全。
要点
- 客观缓解率29.1%,疾病控制率67.7%,不同方案或治疗线数间无差异
- 中位至治疗失败时间6.2个月,中位总生存期9.6个月
- 34.6%患者需剂量调整,停药率9.8%,发生一例毒性相关死亡
核心结论
- 仑伐替尼为基础方案对重度经治的转移性肾细胞癌患者具有活性且安全,作者认为这些发现为其在日常实践中的应用提供了证据支持。
研究设计与样本
- 多中心回顾性研究,纳入2020至2024年间接受仑伐替尼为基础治疗作为一线以上治疗的转移性肾细胞癌患者,共133例,中位年龄61岁。
主要发现
- 透明细胞型为主要亚型,占82.0%;根据IMDC评分, favorable、intermediate和poor风险患者分别占15.8%、51.9%和27.8%。
- 既往中位治疗线数为3线,其中接受过免疫检查点抑制剂者占90.2%,接受过卡博替尼者占90.2%。
- 仑伐替尼单药治疗占45.9%,联合依维莫司占33.8%,联合帕博利珠单抗占18.0%,联合研究性药物占2.3%。
- 客观缓解率为29.1%,疾病控制率为67.7%,不同方案或治疗线数间无差异。
- 中位随访时间13.5个月,中位至治疗失败时间为6.2个月,中位总生存期为9.6个月。
关键数值与推荐
- 客观缓解率29.1%,疾病控制率67.7%。
- 中位至治疗失败时间6.2个月,中位总生存期9.6个月。
- 34.6%的患者需要剂量调整,停药率为9.8%,发生一例毒性相关死亡。
临床怎么用
- 作者认为这些发现为其在日常实践中的应用提供了证据支持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Lenvatinib's activity after immune checkpoint inhibitors (ICI) combination therapy in renal cell carcinoma (RCC) remains unknown. We aimed to describe the real-world outcomes of patients with metastatic RCC (mRCC) treated with lenvatinib after failure of the prior standard of care. METHODS: Multicenter retrospective study including patients with mRCC treated with lenvatinib-based therapies beyond first-line therapy between 2020 and 2024. The primary endpoints were objective response rate (ORR) and time-to-treatment failure (TTF). Secondary endpoints included disease control rate (DCR), overall survival (OS), and safety. RESULTS: We included 133 patients, with a median age of 61 years. Clear-cell was the main subtype (82.0 %). Before lenvatinib treatment, 15.8 %, 51.9 %, and 27.8 % of patients showed favorable, intermediate, and poor risk disease, respectively, according to the International Metastatic RCC Database Consortium (IMDC). Moreover, patients received a median of 3 previous lines of treatment, including ICIs (90.2 %) and cabozantinib (90.2 %). Lenvatinib was given alone (45.9 %) or in combination with everolimus (33.8 %), pembrolizumab (18.0 %) or investigational agents (2.3 %). The ORR and DCR were 29.1 % and 67.7 %, respectively, with no differences between regimens or lines of treatment. With a median follow-up time of 13.5 months, the median TTF and OS were 6.2 and 9.6 months. Toxicity was manageable with dose modifications required in 34.6 %. The discontinuation rate was 9.8 %, with one toxic death. CONCLUSION: Lenvatinib-based regimens were active and safe for heavily pre-treated patients with mRCC. These findings provide evidence to support its use in daily practice.
引用
- Gavira J, Auclin E, Rey-Cardenas M, et al. Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT). Eur J Cancer. 2025. PMID: 40184846. doi:10.1016/j.ejca.2025.115389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。